Three companies completed IPOs this past week, a short four-day trading week due to the Juneteenth holiday. Drug developer Kardigan was the clear winner with a 37.5% first-day pop, the second biotech winner in a row following Parabilis in the prior week,...read more
Kardigan, a Phase 2b/3 biotech developing in-licensed therapies for cardiovascular diseases, raised $400 million by offering 25 million shares at $16, the high end of the $14 to $16 range. The company offered 1.7 million more shares than anticipated. Kardigan ...read more
Two IPOs are currently scheduled to list in the week ahead, although some smaller issuers may also join the calendar throughout the week. Cardiovasular disease biotech Kardigan (KARD) is set to raise $350 million at a $1.6 billion market cap. Kardigan is...read more
Kardigan, a Phase 2b/3 biotech developing therapies for cardiovascular diseases, announced terms for its IPO on Thursday. The Princeton, NJ-based company plans to raise $350 million by offering 23.3 million shares at a price range of $14 to $16. At the...read more
US IPO Weekly Recap: Another biotech IPO pops during the short holiday week
Three companies completed IPOs this past week, a short four-day trading week due to the Juneteenth holiday. Drug developer Kardigan was the clear winner with a 37.5% first-day pop, the second biotech winner in a row following Parabilis in the prior week,...read more
Cardiovascular diseases biotech Kardigan prices upsized IPO at $16, the high end of the range
Kardigan, a Phase 2b/3 biotech developing in-licensed therapies for cardiovascular diseases, raised $400 million by offering 25 million shares at $16, the high end of the $14 to $16 range. The company offered 1.7 million more shares than anticipated. Kardigan ...read more
US IPO Week Ahead: Biotech and community bank set to follow SpaceX’s record debut
Two IPOs are currently scheduled to list in the week ahead, although some smaller issuers may also join the calendar throughout the week. Cardiovasular disease biotech Kardigan (KARD) is set to raise $350 million at a $1.6 billion market cap. Kardigan is...read more
Cardiovascular diseases biotech Kardigan sets terms for $350 million IPO
Kardigan, a Phase 2b/3 biotech developing therapies for cardiovascular diseases, announced terms for its IPO on Thursday. The Princeton, NJ-based company plans to raise $350 million by offering 23.3 million shares at a price range of $14 to $16. At the...read more